Anteris Technologies To Present First 30-Day Clinical And Hemodynamic Outcomes For Its Medium-Size DurAVR Transcatheter Heart Valve At The Transcatheter Cardiovascular Therapeutics Conference, October 31-November 3

Loading news article.

Anteris Technologies To Present First 30-Day Clinical And Hemodynamic Outcomes For Its Medium-Size DurAVR Transcatheter Heart Valve At The Transcatheter Cardiovascular Therapeutics Conference, October 31-November 3 | WAPE

Anteris Technologies To Present First 30-Day Clinical And Hemodynamic Outcomes For Its Medium-Size DurAVR Transcatheter Heart Valve At The Transcatheter Cardiovascular Therapeutics Conference, October 31-November 3

Article summary

Related companies

Comments —